
Minerva Neurosciences (NERV) Stock Forecast & Price Target
Minerva Neurosciences (NERV) Analyst Ratings
Bulls say
Minerva Neurosciences is a promising company with a strong focus on developing and commercializing treatment for CNS diseases, including its promising drug candidate Roluperidone for schizophrenia patients. With positive results from Phase 2b and 3 trials and a planned Phase 3 trial with potential FDA approval in 2029, the market potential for this drug and the company is high. However, there are potential risks and challenges, such as the need for additional funding and securing accurate trial data.
Bears say
Minerva Neurosciences is facing significant clinical risk as their current candidate, Roluperidone, could fail to meet efficacy endpoints or may produce safety signals that impair approval and/or commercialization. With a fully diluted share count of ~111 million shares, the company's $14 price target is derived from a DCF analysis including a 12% discount rate, which is consistent with other development-stage companies. In addition, Minerva ended 2025 with cash and equivalents of ~$82 million, making it necessary for the company to secure further financing in order to continue its operations and commercialization efforts.
This aggregate rating is based on analysts' research of Minerva Neurosciences and is not a guaranteed prediction by Public.com or investment advice.
Minerva Neurosciences (NERV) Analyst Forecast & Price Prediction
Start investing in Minerva Neurosciences (NERV)
Order type
Buy in
Order amount
Est. shares
0 shares